Germany Archives

News and Trends 4 Jun 2015

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

MorphoSys has presented at ASCO optimistic results of MOR202’s phase I/IIa study, a candidate treatment against multiple myeloma. The project was doubted after Celgene’s abandon, but now, safety and efficacy data have shown that there is nothing to worry about. MOR202 is a fully human monoclonal HuCAL antibody targeting CD38, a highly expressed and validated target […]

June 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Last week, Biotech Entrepreneurs gathered in Berlin for the Charité Entrepreneurship Summit 2015. As a spectator, I’ll bring you the most important lessons to take on board from successful entrepreneurs. The First speaker was James Sabry, Senior VP at Genentech, which I already interviewed on the strategy of Genentech/Roche. The Californian entrepreneur, who founded the NASDAQ-listed company Cytokinetics before joining Genentech, gave […]

June 4, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 29 May 2015

Hyglos has a Solution Against Resistant Hospital Germs

Germany-based Hyglos and scientists from the universities of Tübingen, Münster and Munich join forces to develop a phage-based active substance against the dreaded hospital pathogen Staphylococcus aureus. Their secret lies in a highly effective protein from bacteria-specific viruses, the so-called bacteriophages, capable of rapidly killing the bacteria, which frequently occur in the nose. Due to the specific action of this […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 27 May 2015

Berlin’s biotech ecosystem, a fast-growing European hotspot

The Bionnale 2015, a major networking event for biotech in Berlin, is taking place today. Talks about Berlin’s cluster gave me a good insight on what’s happening here. Don’t expect Berlin to be a groundbreaking place like Boston or San Diego. The German capital has more conventional assets, but they’re definitely building a solid ecosystem. With more […]

May 27, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 May 2015

Ipsen acquired OctreoPharm to strengthen its Oncology presence

Ipsen is determined to increase its presence in the oncology field, by acquiring OctreoPharm Sciences. The German life sciences company is focused on the development of radioactive labeled compounds for molecular imaging diagnostics and therapeutic applications. OctreoPharm’s shareholders are eligible to receive up to a total of approximately €50M for the purchase of 100% of […]

May 20, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 May 2015

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next major blockbusters. This new and latest acquisition by Boehringer, is yet another sign of the growing interest for NASH treatments, already chased by companies such as Intercept, Genfit or Gilead. NASH, or non-alcoholic steatohepatitis, is regarded as […]

May 19, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

European companies present their cancer treatment solutions in the USA

Each year, the American Society of Clinical Oncology gathers the cancer therapy developers during five days to present their latest results. Roche seems to be the European winner of this roundup, with amazing results of alectinib in non-small cell lung cancer (NSCLC). Roche’s investigational medicine alectinib shrank tumors in nearly half of patients suffering from this […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

European Union supports Bavarian Nordic to cure Ebola

Bavarian Nordic has been granted €50M loan from the European Investment Bank (EIB) to support the companies’ pipeline including novel vaccines against Ebola and other infectious diseases as well as cancer immunotherapies. The loan is a three-to-five year bullet loan with fixed or variable interest payment. Bavarian Nordic has up to 18 months to draw […]

May 15, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 May 2015

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right now. The latest collaboration in the field has been announced by Eli Lilly and the German Biotech BioNTech. They will identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. Cancers figure […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 May 2015

US-based Juno Therapeutics purchased a German biotech

Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich and Göttingen, Germany. The acquired technologies will support the development of the next generation CAR-T and TCR-T products, bringing Juno one step closer to beating cancer. The transaction further underlines Juno’s strategy of becoming a world leader in process development and in […]

May 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 May 2015

MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

MorphoSys has acquired the Dutch biopharmaceutical company Lanthio Pharma. Morphosys already held 19.98% of Lanthio Pharma and will now pay €20M to purchase all outstanding shares. Thanks to the transaction MorphoSys can add Lanthio Pharma’s lead compound, LP2, to its growing proprietary portfolio. The compound, a novel lanthipeptide in development for diabetic nephropathy and fibrotic […]

May 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 May 2015

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Omeicos Therapeutics has appointed Dr. Ulrich Dauer as Chief Executive Officer. The company, that recently raised €6.2M, enrolled expert Dr. Dauer to advance on its atrial fibrillation treatment. Dr. Dauer will join Omeicos to bring additional leadership expertise as the company builds the infrastructure and capabilities needed to develop its lead therapeutic candidate for atrial […]

May 7, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Germany

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Hyglos has a Solution Against Resistant Hospital Germs

Berlin’s biotech ecosystem, a fast-growing European hotspot

Ipsen acquired OctreoPharm to strengthen its Oncology presence

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

European companies present their cancer treatment solutions in the USA

European Union supports Bavarian Nordic to cure Ebola

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

US-based Juno Therapeutics purchased a German biotech

MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!